Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

The treatment landscape of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the emergence of immune checkpoint inhibitors (ICIs). Although some patients achieve long survival with relatively mild toxicities, not all patients experience such benefits from ICI treatment. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Natsuki, Kawakami, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414869/
https://www.ncbi.nlm.nih.gov/pubmed/36033471
http://dx.doi.org/10.3389/fonc.2022.952393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414869/
https://www.ncbi.nlm.nih.gov/pubmed/36033471
http://dx.doi.org/10.3389/fonc.2022.952393

Ejemplares similares